Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples

Takayuki Iwamoto, Naoki Niikura, Rin Ogiya, Hiroyuki Yasojima, Ken Ichi Watanabe, Chizuko Kanbayashi, Michiko Tsuneizumi, Akira Matsui, Tomomi Fujisawa, Tsutomu Iwasa, Tadahiko Shien, Shigehira Saji, Norikazu Masuda, Hiroji Iwata

Research output: Contribution to journalArticle

Abstract

Our objectives were to determine whether clinic-pathological markers and immune-related gene signatures in breast cancer exhibit any change upon brain metastasis and whether previously reported genes significantly associated with brain metastases and the epithelial-mesenchymal transition (EMT) were reproducible and consistent in our dataset. Sixteen pair-matched samples from primary breast cancers and brain metastases diagnosed were collected from the Japan Clinical Oncology Group Breast Cancer Study Group. Gene expression profiles for immune-, brain metastases-, and EMT-related genes were compared between primary breast cancers and brain metastases. Potential therapeutic target genes of 41 FDA-approved or under-investigation agents for brain metastases were explored. Immune-related signatures exhibited significantly lower gene expression in brain metastases than in primary breast cancers. No significant differences were detected for the majority of genes associated with brain metastases and EMT in the two groups. Among 41 therapeutic target candidates, VEGFA and DNMT3A demonstrated significantly higher gene expression in brain metastases. We found that distinct patterns of gene expression exist between primary breast cancers and brain metastases. Further studies are needed to explore whether these distinct expression profiles derive from or underlie disease status and compare these features between metastases to the brain and other sites.

Original languageEnglish
Number of pages1
JournalScientific reports
Volume9
Issue number1
DOIs
Publication statusPublished - Sep 16 2019

Fingerprint

Transcriptome
Brain Neoplasms
Breast Neoplasms
Neoplasm Metastasis
Brain
Epithelial-Mesenchymal Transition
Genes
Gene Expression
Medical Oncology
Japan
Biomarkers

ASJC Scopus subject areas

  • General

Cite this

Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples. / Iwamoto, Takayuki; Niikura, Naoki; Ogiya, Rin; Yasojima, Hiroyuki; Watanabe, Ken Ichi; Kanbayashi, Chizuko; Tsuneizumi, Michiko; Matsui, Akira; Fujisawa, Tomomi; Iwasa, Tsutomu; Shien, Tadahiko; Saji, Shigehira; Masuda, Norikazu; Iwata, Hiroji.

In: Scientific reports, Vol. 9, No. 1, 16.09.2019.

Research output: Contribution to journalArticle

Iwamoto, T, Niikura, N, Ogiya, R, Yasojima, H, Watanabe, KI, Kanbayashi, C, Tsuneizumi, M, Matsui, A, Fujisawa, T, Iwasa, T, Shien, T, Saji, S, Masuda, N & Iwata, H 2019, 'Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples', Scientific reports, vol. 9, no. 1. https://doi.org/10.1038/s41598-019-50099-y
Iwamoto, Takayuki ; Niikura, Naoki ; Ogiya, Rin ; Yasojima, Hiroyuki ; Watanabe, Ken Ichi ; Kanbayashi, Chizuko ; Tsuneizumi, Michiko ; Matsui, Akira ; Fujisawa, Tomomi ; Iwasa, Tsutomu ; Shien, Tadahiko ; Saji, Shigehira ; Masuda, Norikazu ; Iwata, Hiroji. / Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples. In: Scientific reports. 2019 ; Vol. 9, No. 1.
@article{118c08ef8cb440909628030a047de98d,
title = "Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples",
abstract = "Our objectives were to determine whether clinic-pathological markers and immune-related gene signatures in breast cancer exhibit any change upon brain metastasis and whether previously reported genes significantly associated with brain metastases and the epithelial-mesenchymal transition (EMT) were reproducible and consistent in our dataset. Sixteen pair-matched samples from primary breast cancers and brain metastases diagnosed were collected from the Japan Clinical Oncology Group Breast Cancer Study Group. Gene expression profiles for immune-, brain metastases-, and EMT-related genes were compared between primary breast cancers and brain metastases. Potential therapeutic target genes of 41 FDA-approved or under-investigation agents for brain metastases were explored. Immune-related signatures exhibited significantly lower gene expression in brain metastases than in primary breast cancers. No significant differences were detected for the majority of genes associated with brain metastases and EMT in the two groups. Among 41 therapeutic target candidates, VEGFA and DNMT3A demonstrated significantly higher gene expression in brain metastases. We found that distinct patterns of gene expression exist between primary breast cancers and brain metastases. Further studies are needed to explore whether these distinct expression profiles derive from or underlie disease status and compare these features between metastases to the brain and other sites.",
author = "Takayuki Iwamoto and Naoki Niikura and Rin Ogiya and Hiroyuki Yasojima and Watanabe, {Ken Ichi} and Chizuko Kanbayashi and Michiko Tsuneizumi and Akira Matsui and Tomomi Fujisawa and Tsutomu Iwasa and Tadahiko Shien and Shigehira Saji and Norikazu Masuda and Hiroji Iwata",
year = "2019",
month = "9",
day = "16",
doi = "10.1038/s41598-019-50099-y",
language = "English",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples

AU - Iwamoto, Takayuki

AU - Niikura, Naoki

AU - Ogiya, Rin

AU - Yasojima, Hiroyuki

AU - Watanabe, Ken Ichi

AU - Kanbayashi, Chizuko

AU - Tsuneizumi, Michiko

AU - Matsui, Akira

AU - Fujisawa, Tomomi

AU - Iwasa, Tsutomu

AU - Shien, Tadahiko

AU - Saji, Shigehira

AU - Masuda, Norikazu

AU - Iwata, Hiroji

PY - 2019/9/16

Y1 - 2019/9/16

N2 - Our objectives were to determine whether clinic-pathological markers and immune-related gene signatures in breast cancer exhibit any change upon brain metastasis and whether previously reported genes significantly associated with brain metastases and the epithelial-mesenchymal transition (EMT) were reproducible and consistent in our dataset. Sixteen pair-matched samples from primary breast cancers and brain metastases diagnosed were collected from the Japan Clinical Oncology Group Breast Cancer Study Group. Gene expression profiles for immune-, brain metastases-, and EMT-related genes were compared between primary breast cancers and brain metastases. Potential therapeutic target genes of 41 FDA-approved or under-investigation agents for brain metastases were explored. Immune-related signatures exhibited significantly lower gene expression in brain metastases than in primary breast cancers. No significant differences were detected for the majority of genes associated with brain metastases and EMT in the two groups. Among 41 therapeutic target candidates, VEGFA and DNMT3A demonstrated significantly higher gene expression in brain metastases. We found that distinct patterns of gene expression exist between primary breast cancers and brain metastases. Further studies are needed to explore whether these distinct expression profiles derive from or underlie disease status and compare these features between metastases to the brain and other sites.

AB - Our objectives were to determine whether clinic-pathological markers and immune-related gene signatures in breast cancer exhibit any change upon brain metastasis and whether previously reported genes significantly associated with brain metastases and the epithelial-mesenchymal transition (EMT) were reproducible and consistent in our dataset. Sixteen pair-matched samples from primary breast cancers and brain metastases diagnosed were collected from the Japan Clinical Oncology Group Breast Cancer Study Group. Gene expression profiles for immune-, brain metastases-, and EMT-related genes were compared between primary breast cancers and brain metastases. Potential therapeutic target genes of 41 FDA-approved or under-investigation agents for brain metastases were explored. Immune-related signatures exhibited significantly lower gene expression in brain metastases than in primary breast cancers. No significant differences were detected for the majority of genes associated with brain metastases and EMT in the two groups. Among 41 therapeutic target candidates, VEGFA and DNMT3A demonstrated significantly higher gene expression in brain metastases. We found that distinct patterns of gene expression exist between primary breast cancers and brain metastases. Further studies are needed to explore whether these distinct expression profiles derive from or underlie disease status and compare these features between metastases to the brain and other sites.

UR - http://www.scopus.com/inward/record.url?scp=85072295796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072295796&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-50099-y

DO - 10.1038/s41598-019-50099-y

M3 - Article

C2 - 31527824

AN - SCOPUS:85072295796

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

ER -